Document is current
Any future updates will be listed below
-
Authors
Blackmon, Amanda L. https://orcid.org/0000-0003-0732-0800
Grunwald, Michael R. https://orcid.org/0000-0001-5407-9875
- License Information
-
More Information
Article History
Received: 21 November 2024
Revised: 25 November 2024
Accepted: 28 November 2024
First Online: 11 January 2025
Competing interests
: AB has no COI to disclose. MRG has received consulting fees from Amgen, Aptitude Health, Astellas, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo, GSK, Incyte, Janssen, Jazz, OncLive, Premier, Sanofi, Servier, and Sobi; research funding from Ajax, Incyte, Janssen, and Merck; and has stock ownership in Medtronic.
